Sickle Cell DiseaseNCT04031521
Near Infrared Spectroscopy in Sickle Cell Pediatric Patients
An observational study of Sickle Cell Disease, run by Children's National Research Institute at 1 site in United States.
Trial summary
Endothelial dysfunction contributes to vaso-occlusion and acute pain in sickle cell disease. Near infrared spectroscopy (NIRS) technology can measure tissue oxygenation and endothelial function. Read more about this study
- Who is it for?
- Ages 6 to 21 years
- Conditions the study is for
- Sickle Cell Disease
- What is being tested?
- Near infrared spectroscopy
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Jun 2019to 3 Sep 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 21 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Subjects 6 to 21 years of age of all sickle cell genotypes
Inclusion Criteria for Subjects with Sickle Cell Disease in Pain Crisis:
- Age 6 to 21 years old.
- Diagnosis of sickle cell anemia: a. Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required).
- Acute onset pain crisis in a distribution typical for that subject, onset within the last 7 days and for which hospitalization and parenteral narcotic pain treatment are required.
- Ability to provide informed written consent.
Exclusion Criteria for Subjects with Sickle Cell Disease in Pain Crisis:
- Pregnancy.
- History of non-trivial injury, burns, surgery or skin ulcers on the arms.
- Fever or suspected sepsis at time of pain crisis
- Administration of any of the following drugs within the last 14 days:
- Phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil)
- Endothelin-1 receptor blockers (bosentan, sitaxentan, ambrisentan, tezosentan)
- Nitric oxide donors (nitroglycerin, nitroprusside, nitrates)
- Ingestion of caffeine within the 12 hours before the start of the study appointment, or tobacco use within the 30 days before the study appointment.
- Diagnosis with any of the following chronic diseases or conditions:
- History of high blood pressure
- History of high cholesterol
- History of diabetes
- History of chronic kidney disease (serum creatinine must not be greater than 2 mg/dL)
- History of coronary artery disease or peripheral vascular disease
- Received a blood transfusion within 7 days of the study procedure.
Inclusion Criteria for Subjects with Sickle Cell Disease in Steady State:
- Age 6-21 years
- Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required).
- Ability to provide informed written consent.
Exclusion Criteria for Subjects with Sickle Cell Disease in Steady State:
- Pregnancy.
- History of non-trivial trauma, burns, surgery or skin ulcers on the arms.
- Fever or suspected sepsis at time of pain crisis
- Experience of an acute pain crisis requiring intravenous (IV) narcotics and hospital admission within the last 14 days.
- Ingestion of caffeine within the 12 hours before the start of the study appointment, or tobacco use within the 30 days before the study appointment.
- Administration of any of the following drugs within the last 14 days:
- Phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil)
- Endothelin-1 receptor blockers (bosentan, sitaxentan, ambrisentan, tezosentan)
- Nitric oxide donors (nitroglycerin, nitroprusside, nitrates)
- Diagnosis of any of the following chronic diseases or conditions:
- History of high blood pressure
- History of high cholesterol
- History of diabetes
- History of chronic kidney disease (serum creatinine must not be greater than 2 mg/dL)
- History of coronary artery disease or peripheral vascular disease
- Received a blood transfusion within 7 days of the study procedure.
Trial locations and contacts
1 site in 1 country.
United States1 site
Children's National Medical Center
Washington D.C., District of Columbia, 20010
About this study
Official title: Near-infrared Spectroscopy in Sickle Cell Pediatric Patients During Pain Crisis and After Recovery
Endothelial dysfunction contributes to vaso-occlusion and acute pain in sickle cell disease. Near infrared spectroscopy (NIRS) technology can measure tissue oxygenation and endothelial function. The main objective of this study is to study the natural history of tissue muscle oxygenation using NIRS in pediatric sickle cell subjects experiencing acute pain and pediatric sickle cell patients in steady-state.
- Conditions
- Sickle Cell Disease
- Being tested
- Near infrared spectroscopy
- Medical subject headings
- Anemia, Sickle Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Near infrared spectroscopyDiagnostic test
NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.
| Study group | Role | What they receive |
|---|---|---|
| Sickle cell pain crisis | Not described Receives: Diagnostic Test: Near infrared spectroscopy | |
| Sickle cell steady-state | Not described Receives: Diagnostic Test: Near infrared spectroscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tissue oxygenation
Measured: 6 months
Secondary outcomes (1)
Nitric oxide
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2019
- Study start26 Jun 2019
- Primary completion3 Sep 2023
- Study completion3 Sep 2023
Why it stopped: No eligible patient were available/ found
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sickle Cell DiseaseStudies of the same condition, open and under way.
- More trials run by Children's National Research InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Children's National Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Suvankar Majumdar, Children's National Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04031521
- Sponsor's protocol ID
- Pro00012424
- Status last verified
- Sep 2023
- First submitted
- 22 Jul 2019
- Last updated
- 14 Sep 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Near-infrared Spectroscopy in Sickle Cell Pediatric Patients During Pain Crisis and After Recovery
- ClinicalTrials.gov ID
- NCT04031521
- Acronym / sponsor ID
- Pro00012424
- Conditions
- Sickle Cell Disease
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: No eligible patient were available/ found
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Children's National Research InstituteUniversity, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- Study start
- 26 Jun 2019 (actual)
- Primary completion
- 3 Sep 2023 (actual)
- Study completion
- 3 Sep 2023 (actual)
- First posted
- 24 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Endothelial dysfunction contributes to vaso-occlusion and acute pain in sickle cell disease. Near infrared spectroscopy (NIRS) technology can measure tissue oxygenation and endothelial function. The main objective of this study is to study the natural history of tissue muscle oxygenation using NIRS in pediatric sickle cell subjects experiencing acute pain and pediatric sickle cell patients in steady-state.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sickle cell pain crisis | – | Diagnostic Test: Near infrared spectroscopy |
| Sickle cell steady-state | – | Diagnostic Test: Near infrared spectroscopy |
Who may qualify
- Ages
- 6 to 21 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Subjects 6 to 21 years of age of all sickle cell genotypes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Near infrared spectroscopyNIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin. | Diagnostic test | Sickle cell pain crisis, Sickle cell steady-state |
Primary outcome
Tissue oxygenation
Time frame: 6 months
1 secondary outcome
Nitric oxide
Time frame: 6 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2023.
- Individual participant dataSharing planned: No
Related trials for Sickle Cell Disease
Active, not recruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Sickle Cell Disease, Hemolytic Anemia
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
RecruitingPhase 1
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Sickle Cell Disorders, Sickle Cell Disease
RecruitingPhase 4
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Not yet recruitingPhase 1
Buprenorphine for the Management of Pain in Children With Sickle Cell Disease
Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sickle Cell Disease, run by Children's National Research Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 14 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tissue oxygenation (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2023.